We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+19.28%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$8.67B
AUM Growth
+$1.11B
Cap. Flow
+$178M
Cap. Flow %
2.05%
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$177M
2
ARTV
Artiva Biotherapeutics
ARTV
+$114M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$51.1M
4
BIOA
BioAge Labs
BIOA
+$44.3M
5
PCVX icon
Vaxcyte
PCVX
+$43.7M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$88.9M
2
VRNA
Verona Pharma
VRNA
+$64.6M
3
GERN icon
Geron
GERN
+$63.3M
4
ASND icon
Ascendis Pharma A/S
ASND
+$53.7M
5
URGN icon
UroGen Pharma
URGN
+$51.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANRO icon
51
Alto Neuroscience
ANRO
$1.1B
$23.7M 0.27%
2,075,154
-10,400
-0.5% -$127K
SERA icon
52
Sera Prognostics
SERA
$75.6M
$23.7M 0.27%
3,032,808
– –
TSHA icon
53
Taysha Gene Therapies
TSHA
$1.78B
$21.9M 0.25%
10,872,503
– –
IMTX icon
54
Immatics
IMTX
$1.28B
$20M 0.23%
1,750,000
– –
JBIO
55
Jade Biosciences
JBIO
$1.3B
$19.2M 0.22%
262,631
– –
NUVL
56
DELISTED
Nuvalent
NUVL
$18M 0.21%
176,281
+56,492
+47% +$4.69M
THRD
57
DELISTED
Third Harmonic Bio
THRD
$17.4M 0.2%
1,280,826
-752,230
-37% -$9.32M
VOR icon
58
Vor Biopharma
VOR
$1.21B
$15.9M 0.18%
1,137,444
– –
INSM icon
59
Insmed
INSM
$21.4B
$14.6M 0.17%
200,000
– –
PLRX icon
60
Pliant Therapeutics
PLRX
$65M
$14.4M 0.17%
1,281,000
– –
TNYA icon
61
Tenaya Therapeutics
TNYA
$161M
$13.5M 0.16%
6,982,587
-639,760
-8% -$1.81M
ZURA icon
62
Zura Bio
ZURA
$541M
$13.1M 0.15%
3,217,503
– –
HOWL icon
63
Werewolf Therapeutics
HOWL
$20.1M
$13M 0.15%
6,144,881
– –
CRVO icon
64
CervoMed
CRVO
$25.9M
$11.9M 0.14%
817,120
– –
XNCR icon
65
Xencor
XNCR
$1.48B
$11.6M 0.13%
+575,000
New +$10.8M
ACET icon
66
Adicet Bio
ACET
$86.1M
$10.9M 0.13%
471,313
– –
ARVN icon
67
Arvinas
ARVN
$581M
$10.4M 0.12%
421,348
– –
AVTX icon
68
Avalo Therapeutics
AVTX
$980M
$9.19M 0.11%
+967,000
New +$9.97M
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$8.18M 0.09%
8,800,000
– –
BOLD
70
Boundless Bio
BOLD
$60.9M
$7.57M 0.09%
2,180,631
– –
CDTX
71
DELISTED
Cidara Therapeutics
CDTX
$7.56M 0.09%
+703,080
New +$8.44M
PCSC
72
DELISTED
Perceptive Capital Solutions
PCSC
$7.51M 0.09%
750,000
– –
LXEO icon
73
Lexeo Therapeutics
LXEO
$346M
$4.94M 0.06%
546,554
-126,158
-19% -$1.5M
TARA icon
74
Protara Therapeutics
TARA
$225M
$3.48M 0.04%
1,900,000
– –
ADGM
75
Adagio Medical Holdings
ADGM
$17.8M
$3.44M 0.04%
+1,333,926
New +$6.35M
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, RA Capital Management held 87 positions worth $8.67B, up 15% from $7.56B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management's Q3 2024 filing shows 9 new, 9 increased, 14 reduced and 6 closed positions. Its largest new stake was Bicara Therapeutics: 6,955,993 shares worth $177M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $88.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q3 2024 buy was Bicara Therapeutics: 6,955,993 shares worth $177M.
  • RA Capital Management added most to Vaxcyte in Q3 2024, an estimated $43.7M increase.
  • RA Capital Management's biggest Q3 2024 reduction was Verona Pharma, cutting an estimated $64.6M.
  • RA Capital Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q3 2024, selling an estimated $88.9M.
  • RA Capital Management's ten largest holdings make up 55% of its $8.67B portfolio in Q3 2024.
  • RA Capital Management opened 9 new positions and closed 6 in Q3 2024.
  • RA Capital Management's portfolio value rose 15% quarter-over-quarter to $8.67B.

Based on RA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.